• <strike id="xmwty"><table id="xmwty"></table></strike>
    <progress id="xmwty"></progress>

      <b id="xmwty"></b>

      ×

      Tonghua Dongbao: First subject enrolled in Phase II clinical trial on novel URAT1 inhibitor (THDBH130 Tablets) for gout

      Date:2023-02-08
      Author:東寶
      Views:2

      Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") has enrolled the first subject in the Phase II clinical trial on URAT1 inhibitor (THDBH130 Tablets).

       

      In the field of endocrine and metabolic, the Company gives priority to the development of gout/hyperuricemia treatment. URAT1 inhibitor (THDBH130 Tablets) is among the Company's key novel drugs under research for gout/hyperuricemia treatment. The enrollment of the first subject in the Phase II clinical trial marks another solid step the Company has taken in this field. The Company will accelerate the clinical trial process of the URAT1 inhibitor to address the vast unmet clinical needs and provide patients with more medication choices.

       

      About Phase IIa clinical study of THDBH130 Tablets

      In accordance with relevant guidelines for China's novel drugs, the Company has initiated a multicenter, randomized, double-blind, placebo-and-benzbromarone-controlled Phase IIa clinical study of THDBH130 Tablets in treating adult hyperuricemic patients with or without gout. The Phase IIa study comes after the Company obtained clinical trial approval for the URAT1 inhibitor (THDBH130 Tablets) from the National Medical Products Administration and completed the Phase I clinical trial. The primary purpose of the Phase IIa study is to evaluate the safety, tolerability, and preliminary clinical efficacy of THDBH130 Tablets, and the secondary purpose is to evaluate their uric acid lowering effect, impact on gout attacks, and pharmacokinetic and pharmacodynamic profiles. The trial is working out well, with the first subject enrolled recently.

       

      About THDBH130 Tablets

      THDBH130 Tablets are a highly active, selective, and safe inhibitor of the urate transporter (URAT1). The Phase I clinical trial results show that the drug features low systemic exposure, high pharmacological activity, good safety and tolerability profiles, and better uric acid lowering effect after postprandial administration.

       

      About gout and hyperuricemia

      In recent years, the prevalence of gout and hyperuricemia has obviously increased in China, especially among young people, exposing the vast unmet medical needs in this field. According to the Chinese Guidelines for the Treatment of Hyperuricemia and Gout (2019), the overall prevalence of hyperuricemia and gout in China is 13.3% and 1%-3%, respectively. Gout has become the second most common metabolic disease after diabetes.

       

      There are two main treatments for hyperuricemia and gout: inhibiting uric acid production and increasing uric acid excretion. The existing drugs on the market still have room for improvement in efficacy and safety. Among them, uricosuric drugs targeting URAT1 mainly include benzbromarone and lesinurad. According to data from Menet.com, in 2021, sales of gout drugs at public medical institutions and physical pharmacies across China totaled about RMB 1.878 billion, including about RMB 550 million for benzbromarone. Lesinurad is not yet available in China.


      0 国产在线看片av免费,91中文字幕 国产,国产丝袜脚足j在线视频播放,黄视频在线观看无码免费
    1. <strike id="xmwty"><table id="xmwty"></table></strike>
      <progress id="xmwty"></progress>

        <b id="xmwty"></b>

        a视频在线观看无码| 亚洲人成网欧洲无码不卡| 色狠狠一区二区三区播放| 久精品视在线中文字幕| 欧美精品一二三区| 曰韩无码无遮挡A级毛片777| 国语对白做受69| 无码av午夜福利| 亚洲xxx拳头交| 国产精品中文久久久久久久| 亚洲欧美日韩动漫在线观看| 亚洲一区高清无码精品视频| 亚洲 无码 网友自拍| 国产亚洲无码毛片| 亚洲精品综合色区二区| 色哟哟免费视频一区二区三区| 久久精品在线| 成人三级在线观看| 中文字幕精品视频在线| 亚洲综合偷拍欧美一区| 久久国产精品久久| 无码国产日韩精品一区二区密臂| 亚洲另类欧美日本一区| 国产高清精品在线91| 国产成人永久免费精品| 久久久久中文字幕无码少妇| 亚洲欧美日韩精品久久无广告| 精品无码一区二区视频在线| 无码av在线免费专区|